Expansion Momentum Olpha is actively expanding its manufacturing footprint with a new finished dosage form facility and substantial equipment investments, signaling ongoing capacity growth and opportunities to supply additional raw materials, packaging, or contract manufacturing services to scale with the new plant.

Cardiology Focus The launch of a generic cardiology medication and Olpha's strength in cardiology formulations present a clear entry point for partnerships in API sourcing, formulation development, and regional distribution to support the new product line across Europe.

EU GMP Leadership Olpha’s EU GMP for APIs and FDFs, US FDA alignment for certain APIs, and ISO certifications position it as a trusted supplier for multinational pharma companies seeking compliant manufacturing and potential co-development or tolling arrangements.

Regional Scale With operations spanning Latvia and Northern Europe and a revenue range in the hundreds of millions, Olpha offers an opportunity for strategic suppliers and service providers to align with a regional leader that can consolidate supply chains and reduce lead times in the Baltic and European markets.

Experienced Leadership Long-standing leadership since 2021 with a defined governance structure indicates stability and potential for long-term partnerships, making Olpha an attractive candidate for long-cycle contracts, technology licensing, and strategic collaborations in neurology, infectology, and allergology.